Skip to main content
Log in

Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Introduction

Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia—the measurement of muscle wasting—may be a more objective and comprehensive patient-specific factor associated with long-term survival.

Methods

Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors.

Results

Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm2/m2) was greater than among women (454 mm2/m2). Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49.9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1- and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR = 1.68; P < 0.001). Tumor-specific factors such as poor differentiation on histology (HR = 1.75), margin status (HR = 1.66), and lymph node metastasis (HR = 2.06) were associated with risk of death at 3-years (all P < 0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR = 1.63; P < 0.001).

Conclusions

Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1): 10–5.

    Article  PubMed  Google Scholar 

  2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6): 567–79.

    Article  PubMed  CAS  Google Scholar 

  3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3): 267–77.

    Article  PubMed  CAS  Google Scholar 

  4. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101(6): 908–15.

    Article  PubMed  CAS  Google Scholar 

  5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230(6): 776–82; discussion 82–4.

    Article  PubMed  CAS  Google Scholar 

  6. Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005;92(5): 547–56.

    Article  PubMed  CAS  Google Scholar 

  7. Balzano G, Zerbi A, Capretti G, Rocchetti S, Capitanio V, Di Carlo V. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg 2008;95(3): 357–62.

    Article  PubMed  CAS  Google Scholar 

  8. Balcom JHt, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136(4): 391–8.

  9. Pratt W, Joseph S, Callery MP, Vollmer CM, Jr. POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008;143(1): 8–19.

    Article  PubMed  Google Scholar 

  10. Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg 2006;10(9): 1243–52; discussion 52–3.

  11. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM, Jr. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 2007;245(3): 443–51.

    Article  PubMed  Google Scholar 

  12. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141(5): 610–8.

    Article  PubMed  Google Scholar 

  13. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Annals of surgical oncology 2008;15(1): 165–74.

    Article  PubMed  Google Scholar 

  14. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13(4): 752–9.

    Article  Google Scholar 

  15. Deyle S, Banz VM, Wagner M, et al. Estimation of physiologic ability and surgical stress score does not predict immediate outcome after pancreatic surgery. Pancreas;40(5): 723–9.

  16. Hashimoto D, Takamori H, Sakamoto Y, Tanaka H, Hirota M, Baba H. Can the physiologic ability and surgical stress (E-PASS) scoring system predict operative morbidity after distal pancreatectomy? Surg Today;40(7): 632–7.

  17. Hashimoto D, Takamori H, Sakamoto Y, et al. Is an estimation of physiologic ability and surgical stress able to predict operative morbidity after pancreaticoduodenectomy? J Hepatobiliary Pancreat Sci;17(2): 132-8.

  18. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg;210(6): 901–8.

  19. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford);13(7): 439–46.

  20. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3(4): 269–75.

    Article  PubMed  Google Scholar 

  21. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15(8): 2920–6.

    Article  PubMed  CAS  Google Scholar 

  22. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol;28(2): 340–7.

  23. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol;21(8): 1594–8.

  24. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol;28(6): 1054–60.

  25. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15(22): 6973–9.

    Article  PubMed  CAS  Google Scholar 

  26. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma. Ann Surg Oncol;18(13): 3579–85.

  27. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg;211(2): 271–8.

  28. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250(2): 187–96.

    Article  PubMed  Google Scholar 

  29. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147(8): 755–63.

    Article  PubMed  CAS  Google Scholar 

  30. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004;97(6): 2333–8.

    Article  PubMed  Google Scholar 

  31. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33(5): 997–1006.

    Article  PubMed  Google Scholar 

  32. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. The British journal of surgery 2012.

  33. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annual review of medicine 2011;62: 265–79.

    Article  PubMed  CAS  Google Scholar 

  34. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American journal of clinical nutrition 2006;83(6): 1345–50.

    PubMed  CAS  Google Scholar 

  35. Blum D, Omlin A, Fearon K, et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer;18(3): 273–9.

  36. Ockenga J, Valentini L. Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther 2005;22(7): 583–94.

    Article  PubMed  CAS  Google Scholar 

  37. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005;103(10): 2189–98.

    Article  PubMed  Google Scholar 

  38. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006;61(10): 1059–64.

    Article  PubMed  Google Scholar 

  39. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009;32(11): 1993–7.

    Article  PubMed  Google Scholar 

  40. Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007;30(6): 1507–12.

    Article  PubMed  Google Scholar 

  41. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. The American journal of clinical nutrition 2010;91(4): 1133S–37S.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy M. Pawlik.

Additional information

Peter Peng and Omar Hyder contributed equally to the production of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peng, P., Hyder, O., Firoozmand, A. et al. Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma. J Gastrointest Surg 16, 1478–1486 (2012). https://doi.org/10.1007/s11605-012-1923-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-012-1923-5

Keywords

Navigation